- BNF:
- 10.1.3
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- September 2017
Comments
RED:
- NICE TA466: for moderate to severe rheumatoid arthritis. Selective JAK1/JAK2 inhibitor, JAK3-sparing, treatment of moderate-to-severe active rheumatoid arthritis. (Decision date - September 2017)
- NICE TA681: for the treatment of moderate to severe atopic dermatitis. (Decision date - April 2021)
- For use in monogenic interferonopathies (adults and
children 2 years and over). NHSE commissioned. (Decision date - August 2021)
People admitted to hospital with COVID-19 who need high-flow oxygen: baricitinib can be offered, subject to eligibility criteria, through the UK interim clinical commissioning policies for secondary care. (Decision date - April 2023)
DNP:
- NICE TA926: Baricitinib for treating severe alopecia areata. Baricitinib is not recommended, within its marketing authorisation, for treating severe alopecia areata in adults (Decision date - November 2023)
Do Not Prescribe (DNP) Drug Classifications
- 1: Are classified by the BNF as 'less suitable for prescribing', and includes anti-malarials (where a private prescription may be provided). Have a lack of data on effectiveness compared with standard therapy
- 2: Have a lack of data on safety compared with standard therapy
- 4: Have a lack of data on cost-effectiveness compared with standard therapy
- 5: Less cost-effective than current standard therapy
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
search again